Implications of the incidentalome for clinical pharmacogenomics

Pharmacogenomics

Volumn 14, Issue 11, 2013, Pages 1353-1362

  Brothers, Kyle B ^a   Langanke, Martin ^b   Erdmann, Pia ^c  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

clinical pharmacogenomics; incidental findings; incidentalome; translational genomics

Indexed keywords

ABACAVIR; CLOPIDOGREL; HLA B57 ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MARAVIROC; WARFARIN;

FALSE POSITIVE RESULT; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENTAL FINDING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARMACOGENETICS; PREDICTION; PREVENTIVE MEDICINE; REVIEW; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; WHOLE EXOME SEQUENCING; WHOLE GENOME SEQUENCING; GENOMICS; PROSPECTIVE STUDY;

GENOMICS; GENOTYPE; HUMANS; INCIDENTAL FINDINGS; PHARMACOGENETICS; PROSPECTIVE STUDIES;

EID: 84882287816     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.119     Document Type: Review

References (30)

1. Owens H, Siparsky G, Bajaj L, Hampers LC. Correction of factitious hyperkalemia in hemolyzed specimens. Am. J. Emerg. Med. 23(7), 872-875 (2005).
2. Zandecki M, Genevieve F, Gerard J, Godon A. Spurious counts and spurious results on haematology analysers: a review. Part I: platelets. Int. J. Lab. Hematol. 29(1), 4-20 (2007).
3. Jackson BR. The dangers of false-positive and false-negative test results: false-positive results as a function of pretest probability. Clin. Lab. Med. 28(2), 305-319 (2008).
4. Vernooij MW, Ikram MA, Tanghe HL et al. Incidental findings on brain MRI in the general population. N. Engl. J. Med. 357(18), 1821-1828 (2007).
5. Kohane IS, Masys DR, Altman RB. The incidentalome: a threat to genomic medicine. JAMA 296(2), 212-215 (2006).
6. Hicks JK, Crews KR, Hoffman JM et al. A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin. Pharmacol. Ther. 92(5), 563-566 (2012).
7. Pulley J, Denny J, Peterson J et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin. Pharmacol. Ther. 92(1), 87-95 (2012).
8. Westbrook MJ, Wright MF, van Driest SL et al. Mapping the incidentalome: estimating incidental findings generated through clinical pharmacogenomics testing. Genet. Med. 15(5), 325-331 (2013).
9. Pavlos R, Phillips EJ. Individualization of antiretroviral therapy. Pharmacogenomics Pers. Med. 5, 1-17 (2012).
10. Piga M, Mathieu A. Genetic susceptibility to Behcet's disease: role of genes belonging to the MHC region. Rheumatology (Oxford) 50(2), 299-310 (2011).
11. Salgado M, Simon A, Sanz-Minguela B et al. An additive effect of protective host genetic factors correlates with HIV nonprogression status. J. Acquir. Immune Defic. Syndr. 56(4), 300-305 (2011).
12. O'Donnell PH, Bush A, Spitz J et al. The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin. Pharmacol. Ther. 92(4), 446-449 (2012).
13. Yarnall KSH, Pollak KI, Østbye T, Krause KM, Michener JL. Primary care: is there enough time for prevention? Am. J. Public Health 93(4), 635-641 (2003).
14. Maciosek MV, Coffield AB, Edwards NM, Flottemesch TJ, Goodman MJ, Solberg LI. Priorities among effective clinical preventive services. Am. J. Prev. Med. 31(1), 52-61 (2006).
15. Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and applications. Transl. Res. 154(6), 277-287 (2009).
16. Berg JS, Khoury MJ, Evans JP. Deploying whole genome sequencing in clinical practice and public health: meeting the challenge one bin at a time. Genet. Med. 13(6), 499-504 (2011).
17. Rudnik-Schöneborn S, Langanke M, Erdmann P, Robienski J. [Ethical and legal aspects of handling incidental findings from genetics: challenges and solutions]. Ethik in der Medizin doi:10.1007/s00481-013-0244-x (2013) (Epub ahead of print).
18. Ormond KE, Wheeler MT, Hudgins L et al. Challenges in the clinical application of whole-genome sequencing. Lancet 375(9727), 1749-1751 (2010).
19. Langanke M, Brothers KB, Erdmann P et al. Comparing different scientific approaches to personalized medicine: research ethics and privacy protection. Pers. Med. 8(4), 437-444 (2011).
20. Hegenscheid K, Seipel R, Schmidt C et al. Potentially relevant incidental findings on research whole-body MRI in the general adult population: frequencies and management. Eur. Radiol. 23(3), 816-826 (2013).
21. Langanke M, Erdmann P. [MRI as a scientific examination and the problem of communicating incidental findings, ethical challenges regarding research subjects]. In: Tragfähige Rede von Gott. Festgabe für Heinrich Assel zum 50. Geburtstag am 9. Februar 2011. Theißen H, Langanke M (Eds). Hamburg, Germany, 197-240 (2011).
22. Erdmann P, Langanke M, Assel H. Incidental findings-understanding of risks by research subjects and implications for research ethics. In: Proceedings of the Societas Ethica Annual Conference, The Quest for Perfection. The Future of Medicine/Medicine of the Future. Linköping University Electronic Press, Lugano, Switzerland, 15-38 (2011).
23. Allyse M, Michie M. Not-so-incidental findings: the ACMG recommendations on the reporting of incidental findings in clinical whole genome and whole exome sequencing. Trends Biotechnol. pii, S0167-7799(13)00092-9 (2013).
24. Green R, Berg J, Grody W et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet. Med. 15(7), 565-574 (2013).
25. Khoury MJ. Human Genome Epidemiology (HuGE): translating advances in human genetics into population-based data for medicine and public health. Genet. Med. 1, 71-73 (1999).
26. Marchant GE, Campos-Outcalt DE, Lindor RA. Physician liability: the next big thing for personalized medicine? Pers. Med. 8(4), 457-467 (2011).
27. Halverson CME, Ross LF. Attitudes of African-American parents about biobank participation and return of results for themselves and their children. J. Med. Ethics 38(9), 561-566 (2012).
28. Murphy J, Scott J, Kaufman D, Geller G, Leroy L, Hudson K. Public expectations for return of results from large-cohort genetic research. Am. J. Bioethics 8(11), 36-43 (2008).
29. Ruiz-Canela M, Valle-Mansilla JI, Sulmasy DP. What research participants want to know about genetic research results: the impact of "genetic exceptionalism". J. Empir. Res. Hum. Res. Ethics 6(3), 39-46 (2011).
30. Beskow LM, Burke W. Offering individual genetic research results: context matters. Sci. Transl. Med. 2(38), 38cm20 (2010).